Primecap Management Co. CA Buys Shares of 99,310 Insulet Corporation $PODD

Primecap Management Co. CA bought a new position in shares of Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 99,310 shares of the medical instruments supplier’s stock, valued at approximately $15,120,000. Primecap Management Co. CA owned 0.14% of Insulet at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. NewEdge Advisors LLC lifted its holdings in shares of Insulet by 44.8% in the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after acquiring an additional 64 shares during the last quarter. Cresset Asset Management LLC increased its holdings in Insulet by 7.3% in the 2nd quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock valued at $813,000 after purchasing an additional 177 shares during the last quarter. Cerity Partners LLC increased its holdings in Insulet by 68.7% in the 2nd quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock valued at $5,423,000 after purchasing an additional 7,030 shares during the last quarter. Sei Investments Co. raised its position in Insulet by 27.4% in the second quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock valued at $43,245,000 after purchasing an additional 29,584 shares during the period. Finally, Treasurer of the State of North Carolina raised its position in Insulet by 2.5% in the second quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock valued at $10,290,000 after purchasing an additional 791 shares during the period.

Insulet Stock Up 0.2%

Insulet stock opened at $143.38 on Thursday. The firm has a market capitalization of $9.94 billion, a P/E ratio of 26.80, a P/E/G ratio of 1.13 and a beta of 1.10. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. Insulet Corporation has a twelve month low of $126.40 and a twelve month high of $354.88. The stock’s fifty day simple moving average is $154.52 and its 200-day simple moving average is $182.09.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm had revenue of $801.70 million during the quarter, compared to analyst estimates of $787.39 million. During the same period last year, the business posted $1.17 earnings per share. Insulet’s revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, equities analysts expect that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The stock was acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This represents a 44.63% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.36% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on PODD shares. Robert W. Baird set a $175.00 price target on Insulet in a research report on Thursday, August 6th. Canaccord Genuity Group cut their price objective on Insulet from $249.00 to $179.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Evercore set a $180.00 target price on Insulet in a research note on Monday, July 6th. The Goldman Sachs Group restated a “buy” rating and set a $205.00 target price on shares of Insulet in a report on Wednesday, May 27th. Finally, Jefferies Financial Group dropped their target price on Insulet from $400.00 to $360.00 in a research report on Thursday, May 7th. Fourteen equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Insulet currently has an average rating of “Hold” and a consensus price target of $195.40.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s second-quarter results exceeded expectations, with adjusted EPS of $1.66 versus the $1.47 consensus and revenue of $801.7 million versus estimates of $787.4 million. Revenue increased 23.5% year over year, although investors remain focused on whether the company can sustain growth after its 2026 guidance reset. Can PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat?
• Neutral Sentiment: Insulet is scheduled to participate in the Wells Fargo 21st Annual Healthcare Conference, giving management an opportunity to address Omnipod demand, retention trends, manufacturing quality and its revised outlook. Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
• Neutral Sentiment: Kestra Medical Technologies appointed Curtis Kopf, Insulet’s former global customer-experience executive, to a senior vice president role. The move is not an operating announcement from Insulet, but could draw attention to executive talent movement and customer-support capabilities in the diabetes-device market. Kestra Medical Technologies Names Curtis Kopf Senior Vice President of Customer Experience
• Negative Sentiment: Multiple law firms are publicizing a federal securities class action against Insulet and certain officers, with an August 31 lead-plaintiff deadline. The complaints allege that the company made misleading statements or failed to disclose material information concerning manufacturing controls, product safety and compliance. The lawsuits are allegations, not established findings, but they increase legal, reputational and potential regulatory risks. Faruqi & Faruqi Insulet Securities Class Action Notice
• Negative Sentiment: Investor notices link the lawsuit to two voluntary Omnipod recalls or medical-device corrections affecting approximately 7 million Pods. Analysts reportedly questioned the scope of Insulet’s manufacturing and quality-control problems, cut valuation assumptions and reduced estimates despite management reiterating guidance. These issues threaten investor confidence in the company’s manufacturing story and could lead to additional scrutiny or costs. PODD Shareholder Alert from Levi & Korsinsky

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.